Abacavir, a nucleoside analog reverse-transcriptase inhibitor (NRTIs), generally sold under the brand name Ziagen. Abacavir sulphate is a medication which is basically used in order to prevent and also in the treatment of patients with HIV/AIDS. Like some other nucleoside analog reverse-transcriptase inhibitors (NRTIs), abacavir is also used together with other HIV medications. The use of this drug is not specified by itself. Abacavir is the NRTI (nucleoside analog reverse-transcriptase inhibitors) class of medications, which functions in order to block the reverse transcriptase, an enzyme needed for HIV virus replication. In the class of NRTI, abacavir belongs to the carbocyclic nucleoside. Patients with this medication may experience some adverse effects. Hypersensitivity reactions (HSRs) can be fatal. Hypersensitivity Reactions usually occur during the initial days of the therapy. Symptoms may include fever, rash, nausea, vomiting, malaise or fatigue, loss of appetite, and respiratory symptoms (e.g., cough, shortness of breath). Abacavir (Ziagen) generally comes in the following forms and strengths:
Fixed-Dose Combination Tablets are as follows:
The use of Abacavir tablets are contraindicated in infants below 3 months of age. In overdose circumstances, an overdose victim should immediately seek medical help from their healthcare provider. Interaction: Following are some common established drug and food interactions, which may take place during the co-administration of abacavir. Abacavir is a Drug from the MPR2 inhibitor (Multidrug resistance-associated protein 2 inhibitors) family which could increase the serum concentration of Cabozantinib. Some PIs (Protease inhibitors) such as Ritonavir or Tipranavir may decrease the serum concentration of Abacavir sulfate through induction of glucuronidation. The metabolization of Abacavir is functioned by both the alcohol dehydrogenase as well as glucuronidation. On 18'th December 1998, the U.S. FDA (Food and Drug Administration) approved Abacavir Sulfate. The trade name of abacavir is Ziagen, which contains abacavir sulphate as an active pharmaceutical ingredient commonly called API. Abacavir 300mg (a Protease Inhibitor) shouldn't be added as a single agent when antiretroviral regimens are changed due to loss of virologic response.
0 Comments
|
Details
ArchivesAuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |